Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

Slides:

Advertisements

Similar presentations

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Advertisements

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Sekeres MA et al. Proc ASH 2015;Abstract 908.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib by Jorge.

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study by Neil P. Shah, François.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia by Jose Roman-Gomez, Antonio.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital by Jeffrey E. Rubnitz, Mihaela Onciu, Stanley Pounds,

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar,

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib by Cecelia R. Miller, Amy S. Ruppert,

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E

Revised International Prognostic Scoring System for Myelodysplastic Syndromes by Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine by Raphaelle Fanciullino, Laure Farnault, Mélanie.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes by Caroline J. McNamara, Tony Panzarella,

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Elias Jabbour, MD, Jorge E. Cortes,

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy by Guillermo Montalban-Bravo,

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs by Preetesh Jain, Hagop Kantarjian,

by Naveen Pemmaraju, Hagop M. Kantarjian, Joseph David Khoury, Susan M

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

by Jan J. Cornelissen, and Didier Blaise

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML by Jorge E. Cortes, Martin S. Tallman, Gary.

Cold agglutinin disease

Outcomes in patients with PTCL

Presentation transcript:

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry Pierce, Mark J. Routbort, Elias J. Jabbour, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, H. Deniz Gur, Shimin Hu, Zhuang Zuo, L. Jeffrey Medeiros, Hagop M. Kantarjian, and Joseph D. Khoury BloodAdv Volume 2(15):1807-1816 August 14, 2018 © 2018 by The American Society of Hematology

Sanam Loghavi et al. Blood Adv 2018;2:1807-1816 © 2018 by The American Society of Hematology

Distribution of CMML patients across categories in the 2008 and 2017 WHO classification schemes. Sanam Loghavi et al. Blood Adv 2018;2:1807-1816 © 2018 by The American Society of Hematology

Outcome comparisons for MDS-CMML and MP-CMML. Outcome comparisons for MDS-CMML and MP-CMML. Kaplan-Meier plots for OS (A) and cumulative incidence of AML (B) in treatment-naïve patients stratified by WHO 2008 and 2017 WBC count (FAB-based MP and MDS subgroups)–based subgroups. Sanam Loghavi et al. Blood Adv 2018;2:1807-1816 © 2018 by The American Society of Hematology

Outcome comparisons for 2008 and 2017 blast-based subgroups. Outcome comparisons for 2008 and 2017 blast-based subgroups. Kaplan-Meier plots for OS (A,C) and cumulative incidence of AML (B,D) in treatment-naïve patients stratified by blast-based subgroups. Sanam Loghavi et al. Blood Adv 2018;2:1807-1816 © 2018 by The American Society of Hematology